Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Ioana Hone - Head-Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President-Clinical & Medical Affairs Conference Call Participants Jack Allen - Baird Joe Pantginis - H. C. Wainwright Jason Bouvier - Cantor Fitzgerald Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Second Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird Joe Pantginis - H. C. Wainwright Kristen Kluska - Cantor William Wood - B. Riley Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeuti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird William Wood - B. Riley Securities Kristen Kluska - Cantor Fitzgerald Joe Pantginis - HC Wainwright Joanne Lee - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. An aud ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 ( ...

Start Time: 16:30 January 1, 0000 5:18 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 PM ET Company Participants Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head of IR Conference Call Participants William Wood - B. Riley Securities Rick Miller - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2022 Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...